U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07401992) titled 'Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis' on Jan. 27.
Brief Summary: This study will evaluate the effects of oral semaglutide in combination with topical corticosteroid/calcipotriol on clinical outcomes and metabolic inflammation in patients with plaque psoriasis and overweight/obesity and/or type 2 diabetes mellitus. A total of 62 participants will be randomized to receive either semaglutide plus topical corticosteroid/calcipotriol or placebo plus topical corticosteroid/calcipotriol for 12 weeks. Clinical efficacy will be assessed using the Psoriasis Area and Severity Index (PASI), and qua...